Brokers Offer Predictions for Editas Medicine FY2025 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Editas Medicine in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will earn ($2.10) per share for the year. The consensus estimate for Editas Medicine’s current full-year earnings is ($2.73) per share.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.75) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.75). Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. The firm had revenue of $0.06 million during the quarter, compared to analyst estimates of $3.93 million. During the same period last year, the company posted ($0.55) EPS. The firm’s quarterly revenue was down 98.9% on a year-over-year basis.

A number of other brokerages have also issued reports on EDIT. Wells Fargo & Company downgraded Editas Medicine from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $7.00 to $4.00 in a report on Wednesday, December 11th. Truist Financial cut shares of Editas Medicine from a “buy” rating to a “hold” rating in a report on Friday, December 13th. JPMorgan Chase & Co. downgraded shares of Editas Medicine from a “neutral” rating to an “underweight” rating in a research report on Monday, December 16th. Barclays decreased their target price on shares of Editas Medicine from $5.00 to $3.00 and set an “equal weight” rating for the company in a research note on Friday, December 13th. Finally, Raymond James downgraded shares of Editas Medicine from an “outperform” rating to a “market perform” rating in a research note on Monday, November 4th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Editas Medicine currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Editas Medicine Trading Down 0.8 %

Shares of NASDAQ EDIT opened at $1.21 on Wednesday. The firm has a 50-day moving average of $1.77 and a two-hundred day moving average of $3.19. Editas Medicine has a twelve month low of $1.12 and a twelve month high of $11.58. The company has a market capitalization of $99.89 million, a price-to-earnings ratio of -0.47 and a beta of 1.95.

Institutional Investors Weigh In On Editas Medicine

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers grew its position in shares of Editas Medicine by 2.9% in the second quarter. Rhumbline Advisers now owns 137,986 shares of the company’s stock valued at $644,000 after purchasing an additional 3,862 shares during the last quarter. American Century Companies Inc. increased its position in Editas Medicine by 13.6% during the second quarter. American Century Companies Inc. now owns 126,240 shares of the company’s stock worth $590,000 after acquiring an additional 15,088 shares during the period. Hsbc Holdings PLC raised its stake in Editas Medicine by 148.1% during the 2nd quarter. Hsbc Holdings PLC now owns 104,794 shares of the company’s stock valued at $488,000 after purchasing an additional 62,561 shares during the last quarter. Caxton Associates LP bought a new stake in shares of Editas Medicine in the second quarter valued at about $600,000. Finally, AQR Capital Management LLC grew its position in Editas Medicine by 117.2% during the second quarter. AQR Capital Management LLC now owns 45,890 shares of the company’s stock worth $214,000 after buying an additional 24,758 shares in the last quarter. 71.90% of the stock is currently owned by institutional investors and hedge funds.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.